SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 1

<210> SEQ ID NO 1
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide
<400> SEQUENCE: 1

Thr His Glu Thr Gly Thr Thr Asn Thr Ala Thr Thr Ala Thr Ser Asn
1 5 10 15

What is claimed is:

1. A compound of Formula (I'):

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein

X is
$$-SO_2$$
—, $-SO$ —, or $-C$ ($=O$)—;

Ring Y is 5-membered heterocyclyl or 5-membered heteroaryl with 1-2 heteroatoms selected from the group consisting of N and S;

 ${
m R}^{1A}$ is hydrogen, halogen, optionally substituted alkyl, or —CN:

R² is hydrogen, optionally substituted acyl, optionally substituted alkyl, or an oxygen protecting group;

R³ is halogen, —CN, —SCN, —NO₂, —N₃, optionally substituted alkyl, optionally substituted acyl, optionally substituted alkynyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, optionally substituted sulfonyl, —OR^a, —N(R^b)₂, or —SR^a;

each instance of R^a is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom;

each instance of R^b is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally

substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group; or optionally two \mathbf{R}^b are joined together with the intervening atoms to form optionally substituted heterocyclyl or optionally substituted heteroaryl;

R⁴ is hydrogen, optionally substituted alkyl, or a nitrogen protecting group;

R⁵ is hydrogen, optionally substituted alkyl, or a nitrogen protecting group;

R⁶ is hydrogen, optionally substituted alkyl, or a nitrogen protecting group;

 R^7 is hydrogen, halogen, optionally substituted alkyl, or —CN; and

n is 0, 1, 2, 3, 4, or 5.

2. The compound of claim 1, wherein the compound is of Formula (I-A):

$$(R^3)_{n} \qquad Y \qquad (I-A)$$

$$(R^3)_{n} \qquad Y \qquad X \qquad X$$

$$R^1 \qquad N \qquad N$$

$$R^5 \qquad N \qquad N$$

$$R^5 \qquad N \qquad N$$

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein

X is
$$-SO_2$$
, $-SO_-$, or $-C(=O)$;

Ring Y is 5-membered heterocyclyl or 5-membered heteroaryl with 1-2 heteroatoms selected from the group consisting of N and S;

R¹ is halogen, optionally substituted alkyl, or —CN;

R² is hydrogen, optionally substituted acyl, optionally substituted alkyl, or an oxygen protecting group;

R³ is halogen, —CN, —SCN, —NO₂, —N₃, optionally substituted alkyl, optionally substituted acyl, optionally substituted alkynyl,